Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG
This study has been completed.
Study NCT00037713 Information provided by ImClone LLC
First Received: May 20, 2002 Last Updated: August 19, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma, Small Cell Lung
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Small Cell
Lung Neoplasms
More general conditions related to this trial
Adenocarcinoma
Carcinoma, Neuroendocrine
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
BEC2 Vaccine
Additional drug interventions recognized in this trial
Adjuvants, Immunologic
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
ImClone LLC
Merck KGaA
EORTC Lung Cancer Cooperative Group
Spanish Lung Cancer Group
Schweizerische Arbeitsgruppe fuer angewandte Krebsforschung (SAKK)
Centers of Veterans' Administration
Groupe Francais De Pneumo-Cancerologie
Memorial Sloan-Kettering Cancer Center
Independent centers (Australia, New Zealand, Europe, USA)
Back to top of Main Content
